Amelia Jones | 09/07/2026
The Genomics England Research Summit 2026 highlighted the growing momentum behind genomic newborn screening (gNBS) across research, policy, and implementation. One of the clearest examples was the Generation Study, which has already recruited more than 70,000 participants, returned almost 50,000 results, and identified suspected conditions in 161 newborns. This equates to a prevalence of around 0.32%, remarkably close to the 0.34% central estimate published as part of our research poster, “Estimating the Value of Genomic Newborn Screening in England: A Pragmatic Threshold Analysis”.
Loading Viewer...
This close alignment between observed and predicted prevalence provides an encouraging early indication that the assumptions underpinning our analysis reflect what is being seen in practice. It also reinforces the importance of generating timely evidence to support decisions about the future of genomic newborn screening in England.
Our study was motivated by a practical challenge. Comprehensive economic evaluations across hundreds of rare conditions are complex and time-intensive, but policymakers and healthcare leaders need evidence to inform decisions today. We therefore asked a simple but important question: what level of health benefit would genomic newborn screening need to deliver to represent good value for money?
To answer this we applied a pragmatic threshold analysis; a novel, decision-focused approach. Rather than modelling each condition individually, we synthesised published prevalence and cost data to estimate the average health gains required for gNBS to meet established NICE cost-effectiveness thresholds.
The results were striking because they transformed a complex economic question into a practical benchmark for decision-makers. At an estimated cost of £1,200 per newborn and a birth prevalence of 0.34%, genomic newborn screening would be considered cost-effective if it generated an average gain of 6.9 quality-adjusted life years (QALYs) for each affected infant identified through the programme. Rather than requiring evidence on every individual condition, this provides a clear threshold against which emerging clinical data can be assessed. The key question therefore becomes not whether genomic newborn screening is cost-effective in principle, but whether earlier diagnosis and intervention can realistically deliver this level of health gain for affected children and their families. Attention is then focussed on the factors most likely to determine success: earlier diagnosis, improved clinical outcomes, timely access to treatment, and the NHS’s ability to deliver effective care pathways at scale.
Our analysis complements ongoing work on implementation costs, service design, workforce readiness, and clinical effectiveness by providing a clear framework for interpreting emerging evidence across the programme as a whole.
The strong interest in our poster at the Summit reinforced a key message: understanding the value of genomic newborn screening will be critical to its adoption beyond the research setting. The work resonated with stakeholders because it offers a transparent, practical, and adaptable approach to decision-making, one that can be refined as real-world evidence continues to emerge.
Encouragingly, the project has already opened the door to collaboration with Genomics England, creating opportunities to further strengthen and develop the analysis. For policymakers, researchers, and NHS leaders, the message is clear: early economic signals matter. They help prioritise investment, shape future research, and support evidence-based decisions about implementation.
As the Generation Study continues to evolve – expanding gene lists, refining protocols, and generating new evidence – we look forward to building on this initial work and contributing to the evidence base needed to support the scalable adoption of genomic newborn screening in England.